Two-year follow-up of laser in situ keratomileusis for hyperopia.

To evaluate excimer laser in situ keratomileusis (LASIK) for hyperopia and its predictability.
We performed a retrospective study of 100 eyes that had LASIK for hyperopia to assess predictability and long-term stability of refractive results. The Chiron Automated Corneal Shaper was used to create the flap and the Keracor 117CT Chiron-Technolas excimer laser with the plano-scan program was used to ablate all corneas.
Mean baseline spherical equivalent manifest refraction was +4.50 +/- 1.73 D (range, +1.25 to +8.50 D). Six months after LASIK, mean manifest spherical equivalent refraction was +0.72 +/- 1.87 D (range, -1.75 to +2.50 D), at 1 year, +0.88 +/- 1.73 D (range, -1.25 to +2.50 D), and at 2 years, +0.85 +/- 1.74 D (range, -0.50 to +2.75 D). Two years after LASIK, 45 eyes (74%) were within +/-1.00 D of intended correction and within +/-1.00 D of emmetropia. Uncorrected visual acuity was 20/40 or better in 50 eyes (82%) at 2 years; 29 eyes (37%) saw 20/20 or better. Undercorrection occurred more frequently in eyes with preoperative keratometric power of more than 45.00 D, when ablation zones less than 6 mm were used and when higher amounts of hyperopic correction were required.
LASIK with the Keracor 117CT excimer laser appears to be an effective and safe procedure to correct hyperopia. Preoperative keratometric power, amount of hyperopia, and ablation zone diameter affect the efficacy and long-term stability of the procedure.
AuthorsS Esquenazi, A Mendoza
JournalJournal of refractive surgery (Thorofare, N.J. : 1995) (J Refract Surg) 1999 Nov-Dec Vol. 15 Issue 6 Pg. 648-52 ISSN: 1081-597X [Print] UNITED STATES
PMID10590002 (Publication Type: Journal Article)
  • Adult
  • Follow-Up Studies
  • Humans
  • Hyperopia (surgery)
  • Intraoperative Complications
  • Keratomileusis, Laser In Situ (instrumentation, methods)
  • Postoperative Complications
  • Retrospective Studies
  • Treatment Outcome
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: